Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

NCT05494697 · clinicaltrials.gov ↗
PHASE2
Phase
SUSPENDED
Status
90
Enrollment
INDUSTRY
Sponsor class

Stopped A business decision to place screening/enrollment on hold. Study redesign/amendment pending additional Ampligen-related data from an ongoing Phase I-II open label study (NCT05927142)

Conditions

Interventions

Sponsor

AIM ImmunoTech Inc.

Collaborators